WinSanTor Inc.

WinSanTor Inc. is a biotechnology company focused on creating innovative treatments for peripheral neuropathies, particularly diabetic peripheral neuropathy, through advanced therapeutic solutions. Founded in 2011 in San Diego, US, WinSanTor Inc. specializes in developing treatments for nerve damage.

The company’s lead product, WST-057, is progressing into Phase 2 clinical trials in Canada. The firm was co-founded by Nigel Calcutt and Stanley Kim, who has a history of entrepreneurship. In November 2017, the company raised USD 0. 782 mn from Thynk Capital, marking their latest funding round and totaling USD 0.

780 mn raised to date. WinSanTor Inc. specializes in the development of innovative treatments for peripheral neuropathies, centering on diabetic peripheral neuropathy. Their lead product, WST-057, is designed to repair and regenerate peripheral nerves and has completed Phase 1 clinical trials.

The company targets healthcare providers, patients with nerve-related conditions, and clinical research institutions, primarily marketing solutions in North America while planning for future expansion into additional regions as their clinical programs progress. WinSanTor generates revenue through a clinical trial framework, collaborating with healthcare institutions and research entities. As the company advances through its clinical trials, partnerships will be established for the distribution and commercialization of WST-057 upon receiving regulatory approval. Revenue streams will emerge from agreements with clinical research organizations, healthcare providers, and potentially direct-to-consumer channels following product launch.

WinSanTor aims to launch WST-057 soon, with ongoing Phase 2 trials targeted at patients with diabetic peripheral neuropathy. The company plans to expand its market reach into other regions beyond North America as it progresses with its clinical programs. The recent funding of USD 0. 782 mn from Thynk Capital will support these initiatives, enabling further development and potential commercialization of their treatments.